(−)Deprenyl and (−)1-phenyl-2-propylaminopentane, [(−) PPAP] act primarily as potent stimulants of action potential — transmitter release coupling in the catecholaminergic neurons

This publication has 16 references indexed in Scilit:

• Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes
  Biomedicine & Pharmacotherapy, 1995
• Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: Rationale for prophylactic (-)deprenyl (selegiline) medication
  Life Sciences, 1995
• Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference
  Life Sciences, 1994
• Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
  New England Journal of Medicine, 1993
• (-)Deprenyl-Medication: A Strategy To Modulate the Age-Related Decline of the Striatal Dopaminergic System
  Journal of the American Geriatrics Society, 1992
• Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
  New England Journal of Medicine, 1989
• The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
  Science, 1989
• Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-) deprenyl
  Life Sciences, 1989
• The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenyl
  Mechanisms of Ageing and Development, 1988
• Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985